Wei Chen’s Paper Publication in the Journal for ImmunoTherapy of Cancer (JITC)

Wei Chen’s Paper Publication in the Journal for ImmunoTherapy of Cancer (JITC)

Congratulations to Professor Wei Chen and his lab at the University of Oklahoma for their publication in one of the top ranked oncology and immunology peer-reviewed journals, the Journal for ImmunoTherapy of Cancer (JITC), on their paper, “Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors”. Check out this key publication on how ablation...

RESI Boston 2022 Partnering Platform

Lu Alleruzzo, Co-Founder & CEO, at Immunophotonics, Inc. will be attending the RESI Boston 2022 Partnering Platform, September 21st & 22nd in Boston at the Westin Copley Place.

SACHS Associates 22nd Annual Biotech in Europe Forum

Dr. Theresa Visarius, Immunophotonics Vice President Business Development and Managing Director of the Swiss subsidiary IPS Biopharma AG will be at the SACHS Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment on Wednesday and Thursday, September 21st & 22nd.

Immunophotonics Announces Appointment of New Chief Medical Officer and Chief Scientific Officer

Immunophotonics, Inc. is thrilled to announce the addition of Dr. Edwina Baskin-Bey in the role of Chief Medical Office (CMO) and Dr. David Anderson in the role of Chief Scientific Officer (CSO).  Dr. Baskin-Bey’s vast experience in leading global clinical development and regulatory strategy across multiple therapeutic areas will strengthen the clinical development program as...

Tomas Hode, Wei R. Chen, Siu Kit “Samuel” Lam T Cell Paper Publication

Immunophotonics would like to congratulate Ashley Hoover and Kaili Liu lead authors from the University of Oklahoma and to the co-authors Tomas Hode, Wei Chen, and Sui Kit “Samuel” Lam on the T-Cell Paper publication in Clinical and Translational Medicine July 2022 issue. Check out this pivotal publication on how immunological remodeling of T-cells can...

Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications

Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for treatment of multiple selected cancer indications. This multicenter clinical trial is designed to evaluate the immunologically mediated anticancer effects of intratumorally injecting the company’s lead asset, IP-001, following thermal ablation in patients with advanced solid...

Immunophotonics HEC-TV Interview

Immunophotonics was interviewed by HEC-TV, St. Louis on our lead asset IP-001. Immunophotonics would not be where they are today if it weren’t for the entire team, many of whom are featured in this segment. Great Job Abby Delawder, Chun Fung (Johnny) Wong, Siu Kit (Samuel) Lam, Lu Alleruzzo, Tomas Hode. To View Click Here

Swiss Biotech Day May 2-3, 2022

The Immunophotonics Team is thrilled to announce that Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day on Tuesday, May 3rd in the Clinical Stage Development Company category.

Scroll to top